oral glp-1 drugs in development Four GLP-1R products Phase III trials as race intensifies Evolution of GLP‐1 Receptor Agonists

Together, the outcome could result in serious neurological diseases including ALS, frontotemporal lobar degeneration, Alzheimer's disease, and others (56)

The subthreshold micropulse yellow laser (SMYL) treatment effectively treats macular edema by stimulating retinal pigment epithelial (RPE) cells with light, reducing the number of inflammatory cytokines and hyper-reflective retinal spots (HRS) (Bonfiglio et al., 2022)

Compared with the healthy mice, there was a significant increase in the serum levels of PGE2, CRP, TNF- and IL-6 in the mice with cachexia receiving saline

Get more life from your years Supports graceful aging and longevity* Promotes healthy inflammation response* Supports metabolic function* May help support mental clarity* Promotes balanced energy levels* Designed for overall vitality* Individual experiCompounded medications are not FDA-approved

Funding This research received no specific grant from funding agencies in public, commercial, or non-for-profit sectors